Brought to you by 
Gloucester Pharmaceuticals raises $20.3mm through Series D
27 Aug 2009
Executive Summary
Gloucester Pharmaceuticals (developing treatments for blood cancers) raised $20.3mm through its Series D round, which could close with an additional $8.5mm. New investor Novo AS led and was joined by returning backers Apple Tree Partners, ProQuest Investments, Prospect Venture Partners, and Rho Ventures. Novo takes a seat on Gloucester's board as a result of the financing.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Gloucester Pharmaceuticals raises $20.3mm through Series D
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice